Cardiome Pharma (CRME) Moves Closer to XYDALBA Launch in the UK
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/17/2024
- Stocks decline as interest rate uncertainty, earnings weigh
- ASML slides as Q1 sales fall short but firm still on track for 2025 revenue target
- US dollar weakens as market consolidates gains, but uptrend intact
- Abbott Laboratories (ABT) narrows 2024 earnings guidance, shares slip
- Stocks have priced in much of the 2024 optimism - Wells Fargo
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- ICZOOM Group (IZM) Discloses Request to Withdraw Registration Statement on Form F-1
- Alaska Airlines flights resume after being grounded over aircraft system issue
- GE HealthCare (GEHC) Announces Resignation of Jan Makela, CEO of Imaging
- Barnes & Noble Education (BNED) Enters Definitive Agreement with Immersion (IMMR)
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
- After-hours movers: United Airlines, J.B. Hunt, and more
- Midday movers: Morgan Stanley, UnitedHealth rise; Tesla falls
- Morgan Stanley, UnitedHealth and Bank of America rise premarket; Tesla falls
Cardiome Advances Toward the UK XYDALBA™ (dalbavancin) Launch
November 29, 2016 8:00 AM ESTNASDAQ: CRMEÂ Â TSX: COM
VANCOUVER, Nov. 29, 2016 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) is pleased to announce that it has moved one step closer to launching XYDALBA in the UK by receiving an established price from the Secretary of State for Health, under regulation 3 of the Health Service Branded Medicines Regulations.
Commenting on the development, Hugues Sachot, Senior Vice President Commercial at Cardiome said, "We are extremely pleased with the progress that XYDALBA continues to make toward our imminent launch in the UK and... More
